New drug targets hidden tumor weakness in Hard-to-Treat cancers

NCT ID NCT04954599

Recruiting now Disease control Sponsor: Maastricht University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for adults with solid tumors that have certain genetic features (HRD/FAD) or are growing despite immunotherapy. The experimental drug CP-506 is designed to activate only in low-oxygen areas of tumors, potentially killing cancer cells while sparing healthy tissue. The trial will test CP-506 alone, with chemotherapy (carboplatin), or with immunotherapy, to find the safest dose and see if it helps control the disease. About 126 participants will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Head and Neck Neoplasms metastatic malignant neoplasm ovarian cancer pancreatic neoplasm prostate cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC

Contacts and locations

Locations

Academisch Ziekenhuis Maastricht (Leading Centre)
RECRUITING

Maastricht, Limburg, 6229HX, Netherlands
Erasmus MC
RECRUITING

Rotterdam, Netherlands
Institut Jules Bordet
NOT_YET_RECRUITING

Brussels, Belgium
Institut Vall d'Hebron
NOT_YET_RECRUITING

Barcelona, 08035, Spain
UZ Gent
NOT_YET_RECRUITING

Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.